Carlo Colosimo

Updates on the development of treatments for MSA 2:07
Updates on the development of treatments for MSA
Carlo Colosimo • 16 Sep 2022
MSA: challenges with early diagnosis 2:31
MSA: challenges with early diagnosis
Carlo Colosimo • 16 Sep 2022
Movement disorders in oncology: immune checkpoint inhibitors 2:22
Movement disorders in oncology: immune checkpoint inhibitors
Carlo Colosimo • 16 Sep 2022
Management of iatrogenic hyperkinetic movement disorders 2:58
Management of iatrogenic hyperkinetic movement disorders
Carlo Colosimo • 16 Sep 2022
Recognizing iatrogenic movement disorders 1:58
Recognizing iatrogenic movement disorders
Carlo Colosimo • 16 Sep 2022
DBS & FUS: improvements for the treatment of Parkinson’s disease 1:13
DBS & FUS: improvements for the treatment of Parkinson’s disease
Carlo Colosimo • 27 Jun 2022
Updates on levodopa infusion therapies for advanced Parkinson’s disease 1:27
Updates on levodopa infusion therapies for advanced Parkinson’s disease
Carlo Colosimo • 27 Jun 2022
Genetic testing for dystonia 1:20
Genetic testing for dystonia
Carlo Colosimo • 27 Jun 2022
Advances in Parkinson’s disease biomarkers 1:49
Advances in Parkinson’s disease biomarkers
Carlo Colosimo • 27 Jun 2022
Highlights in Parkinson’s disease: subtyping & prodrome 1:40
Highlights in Parkinson’s disease: subtyping & prodrome
Carlo Colosimo • 27 Jun 2022
Long-term effect of botulinum toxin in cervical dystonia 3:24
Long-term effect of botulinum toxin in cervical dystonia
Carlo Colosimo • 7 Sep 2020
Atypical Parkinsonisms: clinical overview & challenges 3:28
Atypical Parkinsonisms: clinical overview & challenges
Carlo Colosimo • 7 Sep 2020
The content of VJNeurology is intended for healthcare professionals